Focused On-demand Library for Replication factor C subunit 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P40937

UPID:

RFC5_HUMAN

Alternative names:

Activator 1 36 kDa subunit; Activator 1 subunit 5; Replication factor C 36 kDa subunit

Alternative UPACC:

P40937; A8MZ62; B3KSX8

Background:

Replication factor C subunit 5 (RFC5), also known by its alternative names such as Activator 1 36 kDa subunit, plays a crucial role in DNA replication and repair. It functions as a part of the complex machinery that elongates primed DNA templates by DNA polymerase delta and epsilon, necessitating the action of accessory proteins like PCNA and activator 1. This protein's involvement in the fundamental process of DNA synthesis positions it as a key player in cellular proliferation and genome stability.

Therapeutic significance:

Understanding the role of Replication factor C subunit 5 could open doors to potential therapeutic strategies. Its pivotal role in DNA replication and repair mechanisms makes it a promising target for developing novel treatments for diseases characterized by genomic instability.